drugset

drugset / Trial / NCT03064269

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

NCT03064269 ↗

Phase 1 Unknown 10 enrolled Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd The First Affiliated Hospital of Soochow University · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.

Timeline

Start: 2017-03-01
Primary completion: 2024-12-31
Completion: 2025-12-31

Publications

Chen LY, Kang LQ, Zhou HX, Gao HQ, Zhu XF, Xu N, Yu L, Wu DP, Xue SL, Sun AN. Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Transl Oncol. 2020 Nov;13(11):100838. doi: 10.1016/j.tranon.2020.100838. Epub 2020 Jul 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 CAR-T cells	Cell therapy	—	—

Indications